> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Identify Barriers to Enrolling Trial Subgroups: PhRMA
- URL: https://www.fdaweb.com/identify-barriers-to-enrolling-trial-subgroups-phrma/
- Published: 2020-07-09T12:00:00.000Z
- Updated: 2026-09-14T16:20:37.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147161

Pharmaceutical Research and Manufacturers of America (PhRMA) says it appreciates the work FDA has done on advancing the inclusion of diverse populations, including racial and ethnic minorities, in clinical trials. Commenting to the agency docket on strategic priorities for the FDA Office of Minority Health and Health Equity, PhRMA [says](https://www.regulations.gov/contentStreamer?documentId=FDA-2019-N-4824-0060&attachmentNumber=1&contentType=pdf&ref=fdaweb.com) it is important to “identify barriers to enrollment of underrepresented demographic subgroups in clinical trials and employ strategies to encourage greater participation, while also ensuring an efficient drug development process.”

The association suggests that the Office of Minority Health and Health Equity and the biopharmaceutical industry work together to identify and share best practices to advance clinical trial diversity. “PhRMA suggests that this list of best practices includes strategies to increase trust and decrease stigma towards the medical profession, as well as minimize barriers to clinical trial participation while also addressing recruitment and retention of diverse populations,” the group says.

The comment letter also includes specific recommendations.